prod:prod_dcx-login
Seguir
Compartir
Lectura de 3 minutos
23 de septiembre de 2025
SALUD COMUNITARIA Y GLOBAL
Artículo
In Memory of John Bishop: A Visionary Leader in Molecular Diagnostics
We are saddened to learn of the passing of John Bishop, former CEO and Chairman of Cepheid. John led the company from 2002 to 2016, guiding its transformation into a global leader in molecular diagnostics. Under his visionary leadership, Cepheid pioneered breakthrough technologies like the GeneXpert systems, GeneXpert Infinity Systems, and expanded access to life-saving testing around the world. His legacy lives in every GeneXpert cartridge — improving and saving lives throughout the world. We are grateful for his lasting contributions to our company, our industry, and global health.
When John joined Cepheid in 2002, the company was experiencing targeted success in the life sciences market with its first automated PCR platform, the SmartCycler. However, John’s vision was much larger. He envisioned a broad-based clinical company that could expand access to molecular diagnostics well beyond the laboratory — with Cepheid’s GeneXpert platform as the enabling technology. During his 12-year tenure, Cepheid evolved from a novel molecular diagnostics company into a transformative force in healthcare — from anthrax testing at the USPS to methicillin-resistant staph aureus, tuberculosis, flu, Ebola, and many more innovative tests. On its way to placing 10.000 GeneXpert systems worldwide, the company built a legacy of solving complex diagnostic challenges under John’s leadership before attracting acquisition by Danaher Corporation in 2016.
“I am truly honored to have worked closely with John for over 10 years. I joined Cepheid in 2004 because I felt their emerging technology offered the best opportunity to develop tests that could disrupt and democratize diagnostics,” said David H. Persing, M.D., Ph.D. “Under John’s leadership, we built a culture that truly encouraged innovation. John had the unique ability to lead the team in delivering a large menu of clinically relevant tests and, when needed, to also pivot quickly and address emerging public health issues. Cepheid has built a profound legacy that would not have been possible without John’s vision.”
John was also a tireless advocate for diagnostic equity. Through programs like the High Burden Developing Country (HBDC) initiative, he championed access to quality testing for critical diseases in some of the world’s most underserved regions that continue to save lives today.
Before joining Cepheid, John held leadership roles across the biotech and diagnostics landscape, including as CEO of Vysis, MicroProbe, and Gen-Probe. He also served on industry boards such as AdvaMed Dx and received the Ernst & Young Entrepreneur of the Year® award in 2011 for his achievements in life sciences.
John’s leadership left a enduring mark—not only on Cepheid, but on the entire field of molecular diagnostics. His legacy lives on in the technologies he helped create, the people he inspired, and the lives made better by his vision and determination.
Leer siguiente
Más información
